DANIEL RONEY: Open Payments
NPI 1487618690 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,213 in 117 payments from 35 companies in 2025. Trend: 2023 $2,019 · 2024 $2,144 · 2025 $2,213
Food & beverage: $2,213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $298 |
| PFIZER INC. | 17 | $257 |
| Novo Nordisk Inc | 13 | $214 |
| Lilly USA, LLC | 12 | $213 |
| AstraZeneca Pharmaceuticals LP | 4 | $140 |
| Amgen Inc. | 6 | $116 |
| GlaxoSmithKline, LLC. | 5 | $112 |
| Viatris Specialty LLC | 5 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Antares Pharma, Inc. | 4 | $73 |
Products named: VRAYLAR, NURTEC ODT, FARXIGA, MOUNJARO, TRELEGY ELLIPTA, JARDIANCE, YUPELRI, Wegovy.
Industry payments across MO — which companies pay providers there.
